Search Results - "Rédini, F."

DU145 human prostate cancer cells express functional receptor activator of NFκB: New insights in the prostate cancer bone metastasis process by Mori, K, Le Goff, B, Charrier, C, Battaglia, S, Heymann, D, Rédini, F

“…Abstract Prostate cancer metastases to bone are observed in around 80% of prostate cancer patients and represent the most critical complication of advanced…”
Get full text

Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment by Lamoureux, F., Moriceau, G., Picarda, G., Rousseau, J., Trichet, V., Rédini, F.

“…Tumor development in bone is often associated with fractures, bone loss and bone pain, and improvement is still needed in therapeutic approaches. Bone tumors…”
Get full text

Osteosarcoma of the jaws: An overview of the pathophysiological mechanisms by Bertin, Hélios, Gomez-Brouchet, A., Rédini, F.

“…•Jaw osteosarcoma differs from limb osteosarcoma in various clinical and biological parameters.•Changes in crosstalk and the relationship of the tumour to its…”
Get full text

Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells by Ory, B., Moriceau, G., Trichet, V., Blanchard, F., Berreur, M., Rédini, F., Rogers, M., Heymann, D.

“…We recently demonstrated original anti‐tumor effects of zoledronic acid (Zol) on osteosarcoma cell lines independently of their p53 and Rb status. The present…”
Get full text

Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells? by Mori, K, Ando, K, Heymann, D, Rédini, F

“…Primary and secondary bone tumors clearly deteriorate quality of life and the activity of daily living of patients. These undesirable diseases become a major…”
Get full text

Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities by Wittrant, Y, Theoleyre, S, Couillaud, S, Dunstan, C, Heymann, D, Rédini, F

“…Receptor activator of NF-kB Ligand (RANKL) is an essential requirement for osteoclastogenesis and its activity is neutralized by binding to the soluble decoy…”
Get full text

Osteoprotegerin inhibitits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL produced by tumor cells by Picarda, G, Matous, E, Hervouet, S, Lamoureux, F, Trichet, V, Heymann, D, Rédini, F

Get full text

Rankl silencing by sirna improves therapeutic response of primary osteosarcoma to conventional chemotherapy by Rousseau, J, Brion, R, Escriou, V, Battaglia, S, Heymann, D, Rédini, F, Trichet, V

Get full text

RANKL silencing by siRNA improves therapeutic response of primary osteosarcoma to conventional chemotherapy by Rousseau, J, Escriou, V, Lamoureux, F, Brion, R, Battaglia, S, Scherman, D, Heymann, D, Rédini, F, Trichet, V

Get full text

Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B by Mori, K, Le Goff, B, Berreur, M, Riet, A, Moreau, A, Blanchard, F, Chevalier, C, Guisle-Marsollier, I, Léger, J, Guicheux, J, Masson, M, Gouin, F, Rédini, F, Heymann, D

“…RANK, RANK ligand (RANKL) and osteoprotegerin (OPG) are the key regulators of bone metabolism, both in normal and pathological conditions. Previous data have…”
Get full text

Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status by Ory, B, Blanchard, F, Battaglia, S, Gouin, F, Rédini, F, Heymann, D

“…The molecular mechanisms responsible for the cellular effects of the nitrogen-containing bisphosphonate zoledronic acid (Zol) were assessed on several…”
Get more information

Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53 by CHIPOY, C, BROUNAIS, B, TRICHET, V, BATTAGLIA, S, BERREUR, M, OLIVER, L, JUIN, P, REDINI, F, HEYMANN, D, BLANCHARD, F

“…Oncostatin M (OSM), a cytokine of the interleukin-6 family, induces growth arrest and differentiation of osteoblastic cells into glial-like/osteocytic cells…”
Get full text

The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets by David, E., Blanchard, F., Heymann, M. F., de Pinieux, Gonzague, Gouin, F., Redini, Françoise, Heymann, Dominique

“…Chondrosarcomas are malignant cartilage-forming tumours representing around 20% of malignant primary tumours of bone and affect mainly adults in the third to…”
Get full text

RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis by Wittrant, Y., Théoleyre, S., Chipoy, C., Padrines, M., Blanchard, F., Heymann, D., Rédini, F.

“…The emergence of the molecular triad osteoprotegerin (OPG)/Receptor Activator of NF-kB (RANK)/RANK Ligand (RANKL) has helped elucidate a key signalling pathway…”
Get full text

Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models by Rousseau, J, Escriou, V, Perrot, P, Picarda, G, Charrier, C, Scherman, D, Heymann, D, Rédini, F, Trichet, V

“…Osteosarcoma is the most common malignant primary bone tumor for which pertinent preclinical models are still needed to develop new therapeutic strategies. As…”
Get full text

RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases by Baud'huin, M, Lamoureux, F, Duplomb, L, Rédini, F, Heymann, D

“…1997 saw the identification of a novel set of proteins within the tumor necrosis factor (TNF)/TNF receptor families that are required for the control of bone…”
Get full text

Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK by Théoleyre, S, Kwan Tat, S, Vusio, P, Blanchard, F, Gallagher, J, Ricard-Blum, S, Fortun, Y, Padrines, M, Rédini, F, Heymann, D

“…Osteoprotegerin (OPG) is a decoy receptor for receptor activator of nuclear factor kappaB ligand (RANKL), a key inducer of osteoclastogenesis via its receptor…”
Get full text

Therapeutic approach of primary bone tumours by bisphosphonates by Moriceau, G, Ory, B, Gobin, B, Verrecchia, F, Gouin, F, Blanchard, F, Redini, F, Heymann, D

“…Bone tumours can be dissociated in two main categories: i) primary bone tumours (benign or malignant) including mainly osteosarcoma and other sarcomas.ii)and…”
Get more information

Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with receptor activator of nuclear factor κB ligand (RANKL) and RANK by Théoleyre, S., Kwan Tat, S., Vusio, P., Blanchard, F., Gallagher, J., Ricard-Blum, S., Fortun, Y., Padrines, M., Rédini, F., Heymann, D.

“…Osteoprotegerin (OPG) is a decoy receptor for receptor activator of nuclear factor κB ligand (RANKL), a key inducer of osteoclastogenesis via its receptor…”
Get full text

Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma by Heymann, D., Ory, B., Blanchard, F., Heymann, M-F., Coipeau, P., Charrier, C., Couillaud, S., Thiery, J.P., Gouin, F., Redini, F.

“…The efficacy of zoledronic acid (ZOL), with or without the anticancer drug ifosfamide (IFO), was tested on primary bone tumor growth using a rat-transplantable…”
Get full text